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Abstract
Background: Alzheimer's	 disease	 (AD)	 is	 recognized	 as	 one	 of	 the	 greatest	 global	
public	health	challenges.	There	is	increasing	consensus	that	optimal	disease	modifi‐
cation	using	pharmaceuticals	may	best	be	achieved	earlier	in	the	disease	continuum	
before	 symptoms	occur.	However,	more	needs	 to	be	understood	about	what	out‐
comes	are	meaningful	to	potential	participants	in	clinical	trials	within	this	preventa‐
tive	 paradigm	 and	 how	 people	 make	 trade‐offs	 between	 risks	 and	 benefits.	 The	
Electronic	Person‐Specific	Outcome	Measure	(ePSOM)	programme	is	developing	an	
app	to	capture	person‐specific	outcomes	and	preferences	in	clinical	trials.
Objective: As	one	phase	in	the	ePSOM	programme,	this	study	explored	what	matters	
when	developing	new	treatments	to	prevent	AD	and	how	trade‐offs	are	made	be‐
tween	risks	and	benefits,	from	three	perspectives.
Design: Focus	 groups	were	 conducted	with	 people	 living	with	memory	 problems	
(n	=	21)	and	healthy	volunteers	 (n	=	10),	and	 telephone	 interviews	with	health	and	
social	care	professionals	(n	=	10).	Differences	and	overlap	between	the	three	groups	
were explored.
Results: Outcomes	that	matter	lie	in	five	key	domains	in	relation	to	what	matters	in	
everyday	life:	Everyday	Functioning;	Relationships	and	Social	Connections;	Enjoying	
Life;	Sense	of	Identity;	and	Alleviating		Symptoms.	Insights	were	gained	into	the	sig‐
nificance	of	reducing	the	risk	of	developing	dementia	with	drugs	and	the	processes	
of	weighing	up	risks	versus	benefits.
Discussion and conclusions: The	key	domains	identified	are	being	used	to	inform	the	
next	stage	of	the	ePSOM	programme	which	is	to	develop	a	survey	to	be	distributed	
nationally	in	the	UK	to	explore	these	issues	further.
K E Y W O R D S
Alzheimer’s	disease	clinical	trials,	disease	prevention,	focus	groups,	Patient	Preferences,	
Patient‐Reported	Outcome	Measures
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1  | BACKGROUND
Within	health	and	social	care,	a	central	tenet	of	national	policy	is	to	
ensure	 services	work	 to	 support	 people	 to	 achieve	 their	 personal	
outcomes,	defined	as	 the	 things	 important	 to	people	 in	 their	 lives	
and that help them to achieve well‐being.1	A	similar	 focus	on	per‐
sonal	outcomes	has	been	developing	in	parallel	within	clinical	med‐
icine:	 Patient‐Reported	 Outcome	 Measures	 (PROMS)	 assess	 the	
quality	of	care	delivered	to	patients	from	the	patients’	perspectives2 
and	are	increasingly	used	in	clinical	practice	and	in	clinical	trials.
Dementia,	a	syndrome	whose	most	common	form	is	Alzheimer's	
disease	(AD),	is	recognized	as	one	of	the	greatest	global	public	health	
challenges.3	In	the	absence	of	a	cure,	people	with	dementia	require	a	
complex	mix	of	pharmaceutical	and	non‐pharmaceutical	approaches	
to	lessen	their	symptoms	and	help	them	live	in	the	way	that	matters	
to	them.	Evaluating	the	effectiveness	of	such	 interventions	neces‐
sarily	requires	the	use	of	outcome	measures	which	capture	the	range	
of	disease	effects,	not	 limited	to	assessing	cognition	and	the	func‐
tional	 impact	of	cognitive	 impairment	using	pre‐defined	criteria	of	
“normal”	functioning,	but	also	including	outcomes	considered	most	
important	 to	 the	 person	 themselves.	Work	 is	 underway	 to	 estab‐
lish	 a	 core	 outcome	 set	 for	 evaluating	 non‐pharmacological	 inter‐
ventions	for	people	living	at	home	with	dementia.4	In	the	context	of	
the	development	of	pharmaceutical	interventions,	it	is	widely	argued	
that	better	 testing	of	clinical	meaningfulness	and	the	 lived	experi‐
ence	of	individual	patients	is	essential	in	AD	clinical	trials.5‐7
The	 rising	 incidence	 of	 dementia	 and	 associated	 challenges	
in	 health	 and	 social	 care	 provision	 is	 linked	 to	 population	 ageing.	
However,	developments	 in	 imaging	and	molecular	medicine	are	be‐
ginning	 to	 redefine	 our	 understanding	 of	 the	 natural	 development	
of	 dementia,	 leading	 to	 a	 focus	 on	 an	 earlier	 phase	 of	 the	 disease	
continuum.	In	certain	forms	of	dementia,	neuropathological	changes	
associated	with	the	gradual	development	of	dementia	may	precede	
symptomatic	disease	by	decades	(pre‐clinical	stage	of	the	disease).	As	
the	pathology	progresses,	this	eventually	 leads	to	cognitive	change	
where	there	is	no	functional	decline	to	warrant	a	dementia	syndrome	
label	 (prodromal	 Alzheimer's	 dementia),	 before	 finally	 reaching	 a	
state	of	overt	dementia	with	progressive	clinical	severity	(Alzheimer's	
dementia).8,9	There	is	a	belief	that	one	reason	that	clinical	trials	con‐
ducted	involving	individuals	with	dementia	may	have	failed	to	cure	or	
delay	disease	progression	is	because	the	pathological	process	is	too	
far	advanced	for	therapeutic	intervention	to	have	an	effect.10
An	 emerging	 view	 is	 that	 optimal	 disease	 modification	 using	
pharmaceuticals	will	 best	 be	 achieved	 at	 earlier	 stages	of	 the	dis‐
ease	 before	 dementia	 develops.11	 This	 involves	 modification	 of	
the	pathological	process	after	 the	onset	of	disease	but	before	 the	
onset	of	symptoms:	secondary	prevention.10	Individuals	who	are	at	
the	pre‐clinical	and	prodromal	stages	of	the	disease	may	provide	a	
window	 of	 intervention	 opportunity	 before	 overt	 and	 irreversible	
cognitive	change	occurs.	This	has	led	to	a	paradigm	shift	where	AD	
trials	will	 enrol	people	with	mild	and	no	cognitive	 impairment,	 fo‐
cusing	on	the	pre‐dementia	stages	of	the	disease.12	However,	there	
are	methodological	and	analytical	challenges,8	two	of	which	are	the	
focus	of	this	paper.
The	 first	 challenge	 in	 drug	 development	 in	AD	 is	 that	 there	 is	
no	consensus	on	the	optimal	approach	for	outcome	assessment	 in	
dementia	 research,6 particularly within the preventative paradigm 
at	the	earlier	stage	of	the	disease	course.	A	literature	review	by	the	
authors13	concluded	there	are	currently	no	validated	PROMs	used	in	
the	AD	clinical	trials	for	the	early	(pre‐clinical)	stage	of	AD.
The	 second	 challenge	 is	 the	 lack	 of	 understanding	 of	 how	 the	
study	population	view	the	chance	of	detrimental	outcome	versus	ben‐
efit	 in	trials	of	new	preventative	treatments.	Considerations	 include	
the	knowledge	of	personal	 likelihood	of	developing	dementia	 in	the	
future	(hypothetically	or	based	on	biomarkers),	assessment	of	the	sig‐
nificance	of	that	risk,	the	likelihood	of	unwanted	side‐effects	of	pre‐
ventative	treatment	being	tested	and	assessment	of	the	significance	of	
side‐effects.	The	ethical	and	societal	issues	raised	by	the	uncertainty	
of	prognostic	 information	based	on	biomarker	test	results	are	being	
considered.14,15	 A	 survey	 which	 included	 people	 with	 no	 cognitive	
impairment,	people	with	mild	cognitive	 impairment	and	people	with	
a	 diagnosis	 of	 dementia,12	 found	 that	 trials	 enrolling	 pre‐dementia	
populations	may	face	challenges	 in	enrolment,	especially	where	fre‐
quent	visits	and	biomarker	testing	are	required.	The	US	Food	and	Drug	
Administration	(FDA)	and	the	European	Medicines	Agency	(EMA)	pro‐
vide	guidelines	for	side‐effect	risks	that	are	considered	too	great	to	
allow	 for	a	drug	 to	be	 tested.	There	 is	also	 increasing	 interest	 from	
the	FDA	and	the	EMA	about	patient	preferences	and	what	qualifies	
as	a	meaningful	and	relevant	benefit	for	a	patient	in	this	study	popula‐
tion.16,17	Hauber	et	al18	found	that	older	Americans	without	dementia	
see	dementia	as	a	serious	life‐threatening	illness,	although	the	authors	
recognize	the	 limits	of	asking	healthy	volunteers	about	hypothetical	
situations	as	opposed	to	actual	treatment	decisions.
The	electronic	Person‐Specific	Outcome	Measure	(ePSOM)	devel‐
opment	programme	aims	 to	explore	outcomes	and	preferences	 that	
matter	to	“patients”	in	assessing	drug	efficacy	in	Alzheimer's	disease.	
There	 are	 four	 sequential	 stages	 in	 the	 ePSOM	 development	 pro‐
gramme	(a)	literature	review,	(b)	focus	group	study,	(c)	national	survey	
and	(d)	development	of	an	app	for	capturing	person‐specific	outcomes.	
An	overview	of	the	development	programme	incorporating	the	liter‐
ature	 review	 is	 reported	 elsewhere.13	 This	 paper	 reports	 stage	 two	
of	the	ePSOM	programme	and	specifically	addresses	two	of	the	key	
challenges	in	developing	new	treatments	in	AD	(outlined	above):	out‐
comes	that	matter	to	people	and	factors	influencing	risk	decisions.	The	
findings	 of	 this	 empirical	 study	 are	 informing	 the	 development	 of	 a	
UK‐wide	survey	to	explore	the	issues	further—ultimately	leading	to	the	
development	of	an	app,	which	would	incorporate	patient	preferences	
and	capture	PROMs	that	could	be	used	in	AD	clinical	trials.
1.1 | Involving people who experience decline and 
those at risk of developing dementia
As	a	first	step,	it	is	good	practice	to	involve	patients	in	PROM	de‐
velopment.19	The	FDA	recommends	that	patients,	as	well	as	health	
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professionals	and	family	carers,	should	be	 involved	in	 instrument	
item	generation	using	focus	groups	or	interviews.20	This	is	to	en‐
sure	 the	 focus	 is	on	 issues	of	greatest	 importance	and	relevance	
to	patients	and	to	ensure	completeness	and	understanding	of	the	
items	to	be	 included.	The	focus	towards	the	earlier	stages	of	AD	
means	 that	 those	who	might	participate	 in	 trials	 to	develop	new	
treatment,	and	thus	also	in	the	development	of	PROMs,	are	not	yet	
“patients.”	It	is	necessary,	therefore,	to	include	healthy	volunteers.	
However,	the	views	and	experiences	of	people	who	are	living	with	
either	prodromal	or	the	early	stages	of	Alzheimer's	dementia	are	
also	 important	 for	 identifying	 subtle	 changes	 which	 new	 treat‐
ments	might	 prevent	 and	 can	 be	 incorporated	 into	 PROMs.	 It	 is	
necessary	to	understand	more	about	the	attitudes,	beliefs	and	val‐
ues	of	the	target	population	in	the	preventative	model	in	the	pre‐
clinical	stage	who	are	currently	healthy;	people	 in	the	prodromal	
stage	who	are	currently	functioning;	people	with	a	diagnosis	who	
have	already	made	such	decisions	in	relation	to	currently	available	
treatments	 and	 how	 they	 make	 trade‐offs	 between	 benefit	 and	
potential	harm.	The	experiences	of	health	professionals	who	have	
treatment	 discussions	 with	 patients	 experiencing	memory	 prob‐
lems	are	also	relevant.
2  | AIMS
1.	 To	 explore	 what	 outcomes	 matter	 to	 people	 in	 clinical	 trials	
to	 slow	 or	 prevent	 dementia
2.	 To	 explore	 how	 people	make	 decisions	 about	 new	 treatments,	
weighing	up	potential	harms	and	benefits
3.	 To	address	the	above	aims	from	three	perspectives:	
a	 People	experiencing	memory	problems
b	 Healthy	volunteers
c	Health	and	social	care	professionals	(HSP).
3  | METHODS
3.1 | Study design
The	study	comprised	focus	groups	with	healthy	volunteers	and	
people	with	memory	 problems,	 and	 telephone	 interviews	with	
health	and	social	care	professionals	who	provide	care	for	people	
with	dementia.	 It	 is	now	recognized	that	the	subjective	experi‐
ence	of	those	with	mild	and	moderate	dementia	can	be	accessed,	
particularly	when	the	focus	is	on	feelings	rather	than	facts.21,22 
The	 advantages	 of	 using	 focus	 groups	with	 people	with	mem‐
ory	problems	are	that	there	is	 less	pressure	to	contribute	com‐
pared	 to	 individual	 interviews,	 people	 can	 feel	 supported	 and	
empowered	 when	 they	 are	 with	 people	 who	 share	 similar	 ex‐
periences,	 and	 sharing	 experiences	may	 trigger	 recall.21 There 
were	two	focus	groups	with	healthy	volunteers	and	three	focus	
groups	with	people	with	memory	problems.	The	number	of	focus	
groups	was	 based	 on	 the	 resources	 available	 and	 deemed	 suf‐
ficient	 given	 that	 in	 later	 groups,	no	new	 themes	were	arising,	
thus	 achieving	 data	 saturation.23	 Telephone	 interviews	 were	
conducted	with	health	and	social	care	professionals.	Telephone	
interviews	 are	 a	 valid	 and	 recognized	 method	 for	 collecting	
qualitative	data	with	 the	advantage	of	being	 low	cost	 in	 terms	
of	 time	 and	 money	 and	 therefore	 pragmatically	 achievable.23 
The	study	was	approved	by	the	NHS	Research	Ethics	Committee	
(Reference	Number	17/SS/0135).
3.2 | Recruitment and sample
People	 aged	 over	 50	years	 who	 self‐identified	 with	 subjective	
cognitive	 impairment,	 self‐identified	 or	 had	 been	 diagnosed	with	
mild	 cognitive	 impairment	 (MCI)	 or	 been	 diagnosed	 with	 mild	
Alzheimer's	dementia,	or	a	healthy	volunteer	was	recruited	through	
three	routes:
1.	 Join	Dementia	Research	 is	a	partnership	between	the	National	
Institute	of	Health	Research,	Alzheimer's	Scotland,	Alzheimer's	
Society	 and	 Alzheimer's	 Research	 UK	 which	 allows	 people	 to	
register	 their	 interest	 in	 participating	 in	 dementia	 research	
and	 be	 matched	 to	 suitable	 studies,	 with	 consent	 to	 be	 ap‐
proached	 directly	 by	 researchers.	 Nine	 people	 with	 memory	
problems,	 nine	 healthy	 volunteers	 plus	 another	 through	 word	
of	 mouth	 were	 recruited	 through	 this	 route.
2.	 The	 Centre	 for	 Dementia	 Prevention	 at	 the	 University	 of	
Edinburgh	is	a	study	partner	and	holds	a	database	of	people	who	
have	consented	to	be	approached	by	researchers	about	suitable	
studies.	 All	 those	 who	 met	 the	 inclusion	 criteria	 were	 initially	
contacted	by	a	researcher	(JW	or	SS),	sent	an	information	sheet	if	
requested	and	then	followed	up	by	a	phone	call	and	the	opportu‐
nity	to	ask	questions.	Nine	people	with	memory	problems	were	
recruited	through	this	route.
3.	 The	 study	 was	 advertised	 through	 Alzheimer	 Scotland's	 social	
media	networks,	and	those	interested	were	asked	to	contact	re‐
searchers	 directly.	 Three	 people	 with	 memory	 problems	 were	
recruited	through	this	route.
A	 convenience	 sample	 of	 health	 and	 social	 care	 professionals	
known	to	the	research	team	was	invited	to	participate.	This	sampling	
method	is	appropriate	for	the	exploratory	aims	of	the	study.23
3.3 | Data Collection
Data	collection	took	place	between	November	2017	and	February	
2018	at	the	University	of	Edinburgh.	Before	the	focus	groups	began,	
sociodemographic	 data	were	 collected	 from	each	participant.	 The	
sociodemographic	data	collected	are	known	risk	factors	for	demen‐
tia	and	potentially	informative	about	a	person's	understanding	of	the	
concept	of	risks,	trials	and	the	effects	of	dementia.	The	aim	was	to	
gain	an	initial	indication,	in	preparation	for	the	development	of	a	sur‐
vey,	whether	there	are	differences	in	the	responses	by	these	factors.	
Focus	 groups	 lasted	 1.5‐2	hours	 and	 followed	 the	Core	 Principles	
for	 Involving	People	with	Dementia	 in	Research	24.	Relevant	areas	
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explored	 in	 interviews	 are	 shown	 in	 Table	 1.	 Two	 researchers	 fa‐
cilitated	the	groups	(JW,	SS).	Discussions	were	audio	recorded	with	
consent	and	fully	transcribed.	Detailed	notes	were	taken	from	tel‐
ephone	 interviews.	All	 names	were	 removed	 and	each	participant	
given a unique code.
3.4 | Data analysis
Two	researchers	(JW&SS)	undertook	an	initial	reading	of	the	tran‐
scripts	from	the	three	perspectives.	An	initial	list	of	codes	were	in‐
ductively	derived.	Areas	of	agreement	and	disagreement	between	
the	two	researchers	were	discussed	until	agreement	was	reached.	
A	 further	 reading	 of	 the	 transcripts	 was	 undertaken	 by	 JW	 (an	
experienced	 qualitative	 researcher),	 and	 the	 inductively	 derived	
codes	were	 grouped	 into	 two	overarching	 themes	with	 five	 and	
two	subthemes,	respectively.	Repeated	reading	of	the	transcripts	
was	undertaken	by	JW	to	ensure	the	thematic	framework	devel‐
oped	 was	 comprehensive	 and	 covered	 the	 three	 perspectives.	
Data	were	managed	using	NIVIVO	software.	Key	themes	and	data	
coded	to	these	themes	were	presented	to	the	full	study	team	for	
discussion	 and	 consideration	 of	 the	 next	 steps	 in	 developing	 a	
survey.
3.5 | Key findings
The	sample	comprised	41	participants	(Tables	2	and	3)	involving	two	
focus	groups	with	healthy	volunteers,	three	focus	groups	with	peo‐
ple	with	memory	problems	and	ten	telephone	interviews	with	health	
and	 social	 care	 professionals	who	 care	 for	 people	with	 dementia.	
When	focus	group	dates	were	being	arranged	between	participants	
and	researchers,	some	of	those	who	identified	as	having	subjective	
cognitive	 impairment,	but	without	a	 formal	diagnosis	of	dementia,	
opted	to	 join	a	healthy	volunteer	group	and	others	opted	to	 join	a	
group	for	people	with	memory	problems.	This	meant	healthy	volun‐
teer	groups	did	include	some	people	with	subjective	memory	prob‐
lems	and	the	memory	problems	group	contained	people	with	a	range	
of	impairments,	some	of	whom	did	not	have	a	formal	diagnosis.
The	 findings	 are	 organized	 into	 two	 overarching	 themes	 which	
reflect	what	matters	in	developing	treatments	to	prevent	Alzheimer's	
disease:	what	matters	 in	everyday	 life;	what	matters	 in	making	deci‐
sions	about	treatments.	Findings	across	the	three	participating	groups,	
namely	people	with	memory	problems,	healthy	volunteers	and	health	
and	 social	 care	professionals,	 are	 explored	within	 the	narrative	with	
direct	quotes	from	people	with	memory	problems	and	healthy	volun‐
teers	and	detailed	notes	from	professionals	presented	in	Tables	4‐10.
TA B L E  1  Relevant	areas	explored	in	interviews	across	groups
Interview guide for people with subjective memory problems, MCI and mild Alzheimer’s disease
Invite	people	to	tell	their	own	story	of	how	they	make	sense	of	their	condition
•	 What	tells	you	that	you	are	having	a	good	day?
•	 What	tells	you	that	you	are	having	a	bad	day?
•	 Is	there	anything	that	tells	you	that	you	might	be	getting	less	well?
•	 What	are	you	hoping	for	in	life	as	you	think	about	the	future?
We	would	like	to	understand	more	about	what	new	“treatments”	should	do—what	outcomes	matter	to	you—what	would	a	treatment	success	look	
like? 
From	your	own	experience,	which	symptoms	or	effects	do	you	think	are	important	to	target—write	them	on	a	post‐it	note	(optional)
•	 What	makes	you	say	this?
○	 On	the	target	board	can	you	put	them	at	the	centre	if	you	think	they	are	a	top	priority	or	further	out	if	you	think	they	are	less	important.
○	 Other	common	symptoms	are	(prompted	with	those	not	already	mentioned)—where	do	you	think	they	should	go	on	the	target—if	at	all?
•	 What	makes	you	say	this? 
(Prompt	cards—behaviour	changes;	changes	in	mood;	issues	around	care;	disturbed	sleep;	effects	on	Everyday	Functioning;	sensory	changes;	
perceptual	problems;	hallucinations;	loss	of	language;	headaches) 
https://www.alzheimers.org.uk/about‐dementia/symptoms‐and‐diagnosis/symptoms 
We	would	like	to	understand	more	about	how	you	make	choices	about	treatment—when	you	went	to	your	doctor	he	might	have	offered	
several	things:
•	 Advice	about	life	style—stopping	smoking	or	drinking	or	exercise	more
•	 A	tablet	if	one	is	available
•	 Nothing—just	follow	up	every	year	and	do	more	assessments
• Go on a drug trial 
How	did	you	decide	which	one	to	take?	What	would	matter	most	to	you?
•	 What	information	would	you	want	from	your	doctor	to	help	you	make	the	decision?
•	 Most	drugs	have	side	effects—how	would	side	effects	influence	your	decision?
○	 Prompt	Cards—Common	side	effects	include	dizziness,	stomach	problems,	tiredness	or	psychological	problems	such	as	mood	swings.	
https://www.alzheimers.org.uk/about‐dementia/treatments/drugs/effects‐of‐alzheimers‐drugs#content‐start
•	 What	side	effects	would	you	be	prepared	to	cope	with	for	an	improvement?
•	 What	side	effect	would	you	definitely	not	accept?
•	 Would	it	change	your	view	if	the	side	effect	subsided	after	a	period	of	time?
•	 Would	it	change	your	view	if	the	side	effects	were	permanent?
Interview	Guide	for	healthy	volunteers
(Continues)
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3.5.1 | What matters in everyday life
There	were	five	key	 interdependent	subthemes	which	emerged	as	
important	 in	everyday	 life	which	are	 relevant	 to	 considerations	of	
what	matters	in	developing	new	treatments.
Everyday Functioning
People	with	memory	problems	primarily	want	to	be	able	to	keep	con-
fidently	 doing	 taken‐for‐granted	 everyday	 things	 at	 home	 (Table	4	
quote	1),	such	as	doing	laundry	(Table	4	Quote	2).	Not	being	able	to	
care	for	family	through,	for	example	cooking,	led	to	strong	emotions	
Interview guide for people with subjective memory problems, MCI and mild Alzheimer’s disease
We	would	like	to	understand	you	own	experience	of	dementia
•	 Do	you	have	any	personal	experience	with	dementia,	for	example	with	family	members	or	friends?	Can	you	tell	us	something	about	your	
personal	experience?
•	 What	are	you	hoping	for	in	life	as	you	think	about	the	future? 
We	would	like	to	understand	more	about	what	new	‘treatments’	for	dementia	should	do—what	outcomes	matter	to	you?
If	there	was	going	to	be	a	new	treatment	developed	to	slow/alleviate	symptoms	of	dementia	we	would	like	to	understand	which	aspects	of	daily	
life	you	think	would	be	most	important	to	preserve.
From	your	own	experience	or	knowledge	of	dementia,	which	symptoms	or	effects	of	dementia	do	you	think	are	important	to	target	with	
treatment–	write	them	on	a	post‐it	note	(optional)
•	 What	makes	you	say	this?
○	 On	the	target	board	can	you	put	them	at	the	centre	if	you	think	they	are	a	top	priority	or	further	out	if	you	think	they	are	less	important.
○	 Other	common	symptoms	are:	(Prompt	with	those	not	already	mentioned)—where	do	you	think	they	should	go	on	the	target—if	at	all?
•	 What	makes	you	say	this? 
(Prompt	cards—behaviour	changes;	changes	in	mood;	issues	around	care;	disturbed	sleep;	effects	on	Everyday	Functioning;	sensory	changes;	
perceptual	problems;	hallucinations;	loss	of	language;	headaches.) 
https://www.alzheimers.org.uk/about‐dementia/symptoms‐and‐diagnosis/symptoms 
Risk	of	developing	dementia
•	 If	someone	could	tell	you	your	chances	of	developing	dementia	would	you	want	to	know?
Why	would	you	want	to	know?
Why	would	you	not	want	to	know? 
Treatment	trials
•	 If	you	were	offered	the	chance	to	take	part	in	a	clinical	trial	of	a	new	drug	to	reduce	your	risk	of	getting	dementia—what	would	be	your	reason	
for	taking	part?
○	 What	would	you	hope	to	get	from	the	drug?
•	 If	your	risk	of	developing	dementia	was	low,	would	you	consider	taking	part	in	a	drug	trial	to	prevent	it?
○	 What	makes	you	say	that?
•	 If	your	risk	of	developing	dementia	was	medium,	would	you	consider	taking	part	in	a	drug	trial	to	prevent	it?
○	 What	makes	you	say	that?
•	 If	your	risk	of	developing	dementia	was	high,	would	you	consider	taking	part	in	a	drug	trial	to	prevent	it?
○	 What	makes	you	say	that?
•	 What	information	would	you	want	from	your	doctor	to	help	you	make	the	decision?
•	 Most	drugs	have	side	effects—how	would	side	effects	influence	your	decision?
○	 Prompt—Common	side	effects	include	dizziness,	stomach	problems,	tiredness	or	psychological	problems	such	as	mood	swings.	https://www.
alzheimers.org.uk/about‐dementia/treatments/drugs/effects‐of‐alzheimers‐drugs#content‐start
•	 What	side	effects	would	you	be	prepared	to	cope	with	to	prevent	you	getting	dementia
•	 What	side	effect	would	you	definitely	not	accept?
•	 Would	it	change	your	view	if	the	side	effect	subsided	after	a	period	of	time?
•	 Would	it	change	your	view	if	the	side	effects	were	permanent?
Interview	guide	for	health	and	social	care	professionals
•	 Based	on	your	experience	of	treating/caring	for	people	with	Alzheimer’s	disease,	what	would	you	consider	to	be	their	preferred	priorities	in	
treatment?
○	 What	do	you	think	they	hope	to	get	from	treatment?
•	 How	do	you	typically	explain	to	someone	(person	/	carer)	what	the	advantages	and	disadvantages	of	treatment	are?
○	 What	level	of	detail	do	you	use?
○	 What	mode	of	risk	communication	(e.g.	‘most’	people;	1	in	10	people;	7%;	pictograms)
•	 Based	on	your	experience	of	people	with	Alzheimer’s	disease	who	are	involved	in	clinical	trials,	what	do	you	think	they	hope	for	or	expect	in	
taking	part?
•	 What	insights	do	you	have	in	how	people	decide	whether	or	not	to	take	part	in	a	clinical	trial	as	opposed	to	treatment	as	usual?
•	 What	risks	to	do	you	think	people	are	prepared	take	in	agreeing	to	be	part	of	a	clinical	trial?
•	 How	do	you	think	people	weigh	up	risk	versus	benefit?
•	 What	insights	do	you	have	into	why	people	might	drop	out	of	a	clinical	trial?
TA B L E  1   (Continued)
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of	anger	and	frustration	 (Table	4	Quote	3)	and	the	fear	of	being	a	
burden	on	family	(Table	4	Quote	4).
While	maintaining	independence	was	part	of	the	desire	to	retain	
Everyday	 Functioning,	 for	 people	with	memory	 problems,	 it	went	
further	 in	 that	 even	when	help	 is	 needed,	 people	 still	want	 to	 be	
recognized	fundamentally	as	a	person	in	charge	of	themselves	and	
make	their	own	decisions	(Table	4	Quote	5).
Maintaining	Everyday	Functioning	was	echoed	by	healthy	volun‐
teers	(Table	4	Quote	6),	also	picking	up	on	computer	skills	as	being	an	
essential	everyday	function	(Table	4	Quote	7).	Equally,	the	theme	of	
maintaining	Everyday	Functioning	was	underlined	by	health	and	so‐
cial	care	professionals	as	what	matters	most	to	people	with	memory	
problems	(Table	4	Quotes	8	and	9).
Sense of Identity
Linked	with	 the	desire	 to	maintain	Everyday	Functioning	and	coupled	
with	the	need	to	be	recognized	fundamentally	as	a	person	(Table	4	Quote	
5)	was	the	theme	of	Sense	of	Identity.	A	person	with	a	memory	prob‐
lem	spoke	about	how	the	effect	of	losing	confidence	in	doing	taken‐for‐
granted	everyday	things,	coupled	with	other	people	losing	trust	in	their	
ability	to	do	them,	undermined	their	Sense	of	Identity.	This	made	them	
feel	like	they	were	becoming	invisible	as	a	person	(Table	5	Quote	1).
Equally,	 health	 and	 social	 care	 professionals	 recognized	 main‐
taining	a	Sense	of	Identity	in	ways	unique	to	each	person	as	import‐
ant	(Table	5	Quotes	2	and	3).
From	the	perspective	of	healthy	volunteers,	the	loss	of	self‐iden‐
tity	was	not	raised	 in	the	context	of	what	matters	 in	everyday	 life	
but	is	discussed	further	below	in	the	context	of	the	significance	of	
the	risk	of	dementia.
Relationships and Social Connections
Health	 and	 social	 care	 professionals	 identified	 how	 people	 can	 be‐
come	 isolated	 from	their	 social	networks	when	they	have	dementia	
(Table	6	Quote	1)	and	how	people	seek	treatment	to	address	this	issue	
(Table	6	Quote	2).	People	with	memory	problems	revealed	the	mecha‐
nisms	by	which	 this	marginalization	within	social	networks	happens	
and	the	embarrassment	associated	with	it	(Table	6	Quote	3	and	4).
 
People experiencing memory 
problems Healthy volunteers
Total	number	of	participants 21 10
Men 10 5
Women 11 5
Average	age 74.4	y	(58‐89) 63.7	y	(53‐75)
Average	number	of	years	of	
education
14.6	y	(10‐22) 16.3	y	(12‐20)
Ethnicity All	white All	white
Have	children 20 7
Dependants 2 2	participants
Live	with	family 17 4
Live	alone 4 6
Consider	themselves	to	be	having	
memory	problems
21	(all) 4
Dementia	diagnosis 12 0
Diabetes	diagnosis 2 1
Heart	conditions 3 1
Arthritis	diagnosis 2 3
Cancer	diagnosis 2 1
Depression/anxiety 9 3
Annual	household	income	of	focus	group	participants
£0‐£24 000 10 6
£24	001‐£60	000 9 3
More	than	£60	000 0 1
Do not know 2 0
TA B L E  2  Participant	demographics:	
people	experiencing	memory	problems	
and	healthy	volunteers
TA B L E  3  Health	and	social	care	professionals
Characteristics Value
Total	number	of	participants 10
Men 4
Women 6
Medical	professionals 4
Nursing	professionals 4
Social	care	professionals 2
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At	 the	beginning	of	 focus	groups	with	healthy	volunteers,	 they	
were	asked	if	they	had	any	personal	experience	of	dementia,	either	
with	 family	or	 friends.	Nine	of	 the	 ten	healthy	volunteers	did	have	
personal	experience,	eight	with	a	close	family	member	and	one	with	a	
close	friend.	Most	healthy	volunteers	therefore	had	experience	of	the	
effect	that	dementia	has	on	those	around	the	person	with	dementia.	
As	highlighted	above,	people	with	memory	problems	recognized	the	
negative	effect	of	losing	social	connections,	brought	about	in	part	by	
the	embarrassment	of	forgetting	words	and	other's	reactions	to	this.	
In	contrast,	healthy	volunteers	did	not	fully	appreciate	the	 implica‐
tions	of	 forgetting	names	 for	 the	person	 themselves,	but	 saw	 it	 as	
less	important	than	other	effects	of	dementia,	as	it	has	less	impact	on	
those	around	the	person	with	dementia	(Table	6	Quote	5).
Enjoying Life
Connected	to	all	of	the	above	was	the	theme	of	Enjoying	Life,	recog‐
nized	across	all	groups	as	an	important	aspect	of	everyday	life	and	
therefore	an	important	measure	of	the	effectiveness	of	treatment.	
TA B L E  4  Everyday	Functioning	from	the	perspective	of	people	with	memory	problems,	healthy	volunteers	and	health	and	social	care	
professionals	(Each	quote	labelled	with	quote	number	plus	unique	identifier	code	of	each	participant)
People with memory problems Healthy volunteers Health and social care professionals
(1)	I've	lost	a	huge	amount	of	confidence	over	
the	last	year…	and	it's	a	horrible	thing,	
because	you	go	from	somebody	who's	been	
very	confident,	and	leads	a	lot	of	things,	does	
a	lot	of	things	at	home…	and	then	suddenly	
you	find	that…	your	daughter	is,	you	know,	in	
my	case,	they're	taking	over.	(Quote	1	013)
(6)	Just	functioning	with	activities	of	daily	
living,	do	you	know?	If	you've	no	recollec‐
tion	that	you've	not	washed	yourself,	you're	
likely	to	go	out	and	have	issues,	do	you	
know?	So	if	you	can	remember	what	you	
have	to	do,	if	you	can	remember	how	to	
drive	a	car,	then	you	can	take	your	dog	
down	for	a	nice	walk	on	the	beach	(Quote	6	
001)
(8)	Day	to	day	people	want	to	“do	for	
themselves”—prepare	a	meal,	do	their	own	
washing,	potter	about	in	their	own	house,	
be	able	to	choose	what	channel	they	want	
to	watch	on	TV—basic	things.	(Quote	8	
HSPOO7)
(2)	Basically	just	being	able	to,	sort	of,	you	
know,	doing	the	laundry,	and	things	like	that	
(Quote	2	016)
(7)	Being	able	to	function	on	the	computer…I	
mean,	that's	my	source	of	information,	you	
know,	I'd	want	to	be	able	to	keep	that. 
(Quote	7	006)
(9)	Driving	is	a	huge	thing	that	really	affects	
people's	mood—it	is	a	huge	blow	if	they	are	
told	they	can't	drive	as	it	affects	their	
independence—it	has	a	more	negative	
impact	than	the	diagnosis	itself.	(Quote	9	
HSP006)
(3)	You	suddenly	realise	you	can't	do	what	you	
used	to	be	able	to	do.	That	leads	to	frustra‐
tion,	and	anger	comes	after	frustration—not	
being	able	to	look	after	my	partner….at	some	
point	maybe	I	won't	be	able	to	cook	for	him	
(Quote	3	020)
(4)	“The	thought	of	my	children	looking	after	
me,	it's	just	horrendous”	(Quote	4	013)
(5)	Most	people	would	be	prepared	to	say,	well,	
would	you	help…	but	it's	the	fact	of	getting	up	
in	the	morning	and	deciding	what	you're	going	
to	wear	and	how	you…if	you're	going	to	have	
a	shower,	when	you're	going	to	have	a	
shower…you	want	to	be	in	charge	of	your	own	
person.	(Quote	5	022)
People with memory problems Healthy Volunteers
Health and Social Care 
Professionals
(1)	My	husband	doesn't	let	me	do	things,	
like	I	can't	iron…in	case	I	leave	it	on	the	
end	and	walk	away…he	says,	come	on	
hen,	just	leave	it,	and	I'll	get	it.	It's	like	
I'm	not	there.	It's	difficult…it's	a	
woman's	thing	to	go	and	do	washing	
and	ironing	(Quote	1	012)
N/A (2)	People	[want]	to	
remain	the	same	in	
terms	of	their	own	
self‐image,	who	they	
are,	their	status,	their	
role,	their	life	as	they	
live	it	(Quote	2	
HSP004)
(3)	How	they	are	
viewed by other 
people	is	at	the	
forefront…all	linked	
to	identity	(Quote	3	
HSP005)
TA B L E  5  Sense	of	Identity	from	the	
perspective	of	people	with	memory	
problems,	healthy	volunteers	and	health	
and	social	care	professionals	(Each	quote	
labelled	with	quote	number	plus	unique	
identifier	code	of	each	participant)
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People	with	memory	problems	wanted	 to	keep	doing	 the	hobbies	
they	enjoyed	throughout	their	life	(Table	7	Quote	1).	Average	ages	
are	shown	in	Table	2,	as	are	the	number	of	people	living	with	condi‐
tions	 such	 as	 arthritis.	 There	was	 a	 recognition	 that	 being	 able	 to	
enjoy	life	needs	to	be	addressed	in	the	context	of	other	changes	that	
happen	to	ageing	bodies	(Table	7	Quote	2).
During	focus	groups,	 including	with	healthy	volunteers,	a	wide	
range	of	activities	which	help	people	enjoy	life	were	mentioned,	the	
continuation	of	which	people	felt	would	be	an	indicator	of	treatment	
effectiveness	(Table	7	Quote	3).
Health	and	social	care	professionals	also	recognized	the	impor‐
tance	of	Enjoying	Life,	but	also	how	what	 is	enjoyable	varies	 from	
person	to	person	(Table	7	Quote	4).
Alleviating Symptoms
Among	the	already	known	symptoms	of	dementia	 (see	Table	1	for	
prompts	 used),	 people	 experiencing	 memory	 problems	 prioritized	
“memory”	as	the	most	difficult	symptom	and	an	important	target	for	
treatment.	In	terms	of	outcomes	of	treatment,	people	with	dementia	
wanted	to	see	memory	restored	(Table	8	Quote	1).	However,	during	
discussions	it	was	clear	that	they	knew	this	was	what	they	wished	
and	hoped	for	rather	than	a	realistic	expectation	–	“you	are probably 
kidding yourself on” (013):
Worries	 about	behavioural	 changes,	 such	as	becoming	violent,	
also	were	an	important	symptom	for	treatments	to	target	for	people	
with	memory	problems	(Table	8	Quote	2).
Healthy	volunteers	also	prioritized	memory	as	 the	key	symptom	
affecting	quality	of	life	(Table	8	Quote	3).	There	was	an	acknowledge‐
ment	that	there	may	be	other	symptoms	that	are	important	but	that	
the	one	most	commonly	associated	with	dementia	is	memory	(Table	8	
Quote	4).
Health	 and	 social	 care	 professionals	 did	 not	 prioritize	 im‐
proved	memory	as	an	indicator	of	effectiveness	of	treatment	as	
highly	 as	 others.	While	 they	 recognized	memory	 as	 important,	
in	 their	 experience,	 they	 had	 seen	 people	 benefit	 from	 treat‐
ments	 and	 support	 through	 regaining	 confidence	 in	 Everyday	
Functioning,	 even	 if	 their	 scores	 on	 memory	 tests	 did	 not	 im‐
prove	(Table	8	Quote	5).
Health	 and	 social	 care	 professionals	were	more	 likely	 to	men‐
tion,	without	prompting,	symptoms	of	dementia	other	than	memory	
People with memory problems Healthy volunteers
Health and social care 
professionals
(3)	Sometimes	it's	words,	there's	
this	peculiar	sort	of	thing	that	
comes	over	me.	I'll	be	sitting	
talking	to	somebody,	I'm	
carrying on a nice little 
conversation	and	feel	quite	
comfortable,	and	then	suddenly	
just	begin	to	feel	myself	wilting	
almost,	and	the	sensation	is	sort	
of,	oh	no,	I'm	going	to	forget	
what	I	want	to	say	again,	and	
then	it	takes	me	a	few	minutes	
to	recompose	myself,	and	it's	
frustrating	because	I've	got	a	
friend	looking	at	me,	wondering	
what's	going	to	be	said	next,	
and	it's	just	embarrassing.	
(Quote	3	019)
(5)	Forgetting	names,	and	
dates	of	birth,	and	things	
like	that	[are	more	
peripheral].	Because	it	
doesn't	really	affect	your	
daily	life,	it	doesn't	have	a	
massive	impact	on	other	
people.	Whereas,	not	
being	able	to	feed	yourself,	
massive	impact,	you	know,	
somebody	having	to	go	in	
every	single	day.	(Quote	5	
008)
(1)	“They'd	maybe	have	a	
weekly	golf	game	with	
their	pals	they	had	worked	
with that they liked to go 
to	but	found	they	weren't	
being	invited	to	those	any	
more…	because	they	
thought	their	friends	
would think they were 
going	to	go	crazy	or	do	
something	wrong,	hurt	
themselves,	or	weren't	
able	to	do	what	they	set	
out	to	do	together.”	(Quote	
1	HSP005)
(4)	I	was	always	very	sociable,	
and	since	I	developed	dementia,	
I	wanted	to	stay	at	home	
because	I	was	embarrassed	
when	I	made	mistakes	when	I	
was	speaking	to	people	(Quote	
4	025)
 (2)	People	want	“treatment”	
that	has	its	foundation	in	a	
social	aspect	because	they	
find	when	they	get	a	
diagnosis	of	dementia	
their	support	network	or	
social	group	tends	to	
diminish	quite	quickly	eg	if	
they were working and can 
no longer work they look 
for	“treatments”	that	aim	
to	keep	them	as	a	valued	
member	of	society	in	some	
way	or	another	(Quote	2	
HSP005)
TA B L E  6  Relationships	and	Social	
Connections	from	the	perspective	of	
people	with	memory	problems,	healthy	
volunteers	and	health	and	social	care	
professionals	(Each	quote	labelled	with	
quote	number	plus	unique	identifier	code	
of	each	participant)
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problems,	 for	example	 “Sleep disturbance. A good outcome for them 
might be a better night's sleep” HSP	002.
3.5.2 | What matters in making decisions 
about treatments
This	section	explores	the	theme	of	what	matters	in	making	decisions	about	
treatments	and	explores	two	subthemes	identified	as	important	in	weigh‐
ing	the	chance	of	detrimental	outcome	of	treatments	against	benefit.
The significance of reducing the risk of dementia with drugs
This	 subtheme	 came	 from	 data	 collected	 from	 healthy	 volunteers	
only.	It	was	not	explored	with	those	who	were	in	the	memory	prob‐
lem	group	 and	prevention	of	 dementia	 using	drugs	was	not	 some‐
thing	the	health	and	social	care	staff	had	experienced	with	their	own	
patients.
For	some	healthy	volunteers,	dementia	and	particularly	loss	of	mem‐
ory	was	seen	as	a	problem	worth	trying	to	prevent,	even	if	the	chances	
of	developing	these	were	less	than	30	per	cent	(Table	9	Quote	1).
Previous	 family	 experiences	 of	 caring	 for	 someone	 with	 de‐
mentia,	and	experiencing	 this	as	burdensome,	also	 influenced	per‐
ceptions	of	dementia	and	the	significance	of	preventing	it	 (Table	9	
Quote	2).	This	 links	with	the	section	above	in	relation	to	Everyday	
Functioning	and	not	becoming	a	burden	being	what	matters	to	peo‐
ple.	Some	of	the	fear	of	developing	dementia	in	the	future	was	also	
linked	 to	 previous	 experiences	 of	 relatives	who	were	 cared	 for	 in	
care	homes	(Table	9	Quote	3).
However,	in	terms	of	prevention,	people	also	grappled	with	the	
complexity	of	disentangling	change	in	memory	associated	with	nor‐
mal	ageing	from	changes	due	to	dementia	(Table	9	Quote	4).
Balancing risk against benefits
There	were	 two	 categories	 of	 risk	 considered	 in	 relation	 to	 the	
decision‐making	about	preventative	treatments:	the	risk	of	devel‐
oping	dementia	and	the	risk	of	side‐effects	of	drugs.	In	the	current	
context	 of	 no	 cure	 for	 dementia,	 knowing	 your	 risk	 of	 develop‐
ing	dementia	was	 seen	as	unhelpful	 by	 some	healthy	volunteers	
(Table	10	Quote	1).
TA B L E  7  Enjoying	life	from	the	perspective	of	people	with	memory	problems,	healthy	volunteers	and	health	and	social	care	professionals	
(Each	quote	labelled	with	quote	number	plus	unique	identifier	code	of	each	participant)
People with memory problems Healthy volunteers
Health and social care 
professionals
(1)	I	need	my	memory	to	be	able	to	drive	
and	get	out	to	golf.	I	need	to	be	able	to	put	
the	golf	clubs	in	the	car.	Losing	this	would	
have	a	big	effect	because	this	is	how	I	have	
lived	my	life	(Quote	1	021)
(3)	“I	don't	mind	if	I	can't	do	a	cryptic	crossword,	I	would	
really	mind	if	I	couldn't	jump	in	the	car	with	my	dog,	drive	
him	somewhere	and	go	for	a	long,	long	walk	in	the	
morning…I'll	be	wanting	a	drug	that	enables	me	to	do	that,	
so	therefore	it's	got	to	keep	my	muscles	fit,	it's	got	to	keep	
my	ability	to	drive,	my	eyesight's	got	to	be	good,	so	there	are	
so	many	different	things	that	come	into	it.”	(Quote	3	003)
(4)	The	frustrating	things	are	
when	they	can't	do	hobbies	eg	in	
a	choir	and	can't	keep	track	of	
the	music,	or	in	a	book	group	
and	can't	follow	the	thread	of	
the	story—these	things	are	
individual	to	each	person	and	it	
is	important	to	them	to	find	a	
way	of	doing	them.	(Quote	4	
HSP	006)
(2)	And	if	the	person	has	a	hobby	that's	
music	and	they	can't	hear,	but	if	they	can	
hear	and	they've	got	sore	knees,	that's	not	
so	important,	but	if	their	hobby	is	playing	
golf	and	they've	got	sore	knees,	that	is	
important,	so…Quote	2	022
TA B L E  8  Alleviating	Symptoms	from	the	perspective	of	people	with	memory	problems,	healthy	volunteers	and	health	and	social	care	
professionals	(Each	quote	labelled	with	quote	number	plus	unique	identifier	code	of	each	participant)
People with memory problems Healthy Volunteers Health and Social Care Professionals
(1)	I	think	memory	is	the	big	issue	for	a	lot	of	
people,	I'm	not	saying	everybody.	But	
suddenly	starting	to	remember	names	again,	
and	you	know,	remembering	words	again.	Just	
everything,	basically,	because	all	the	things	
you've	lost,	you	want	to	see	them	come	back	
out	again…	that's	more	important	for	me	than	
anything	else.	(Quote	1	013)
(3)	I	think	memory	must	be	one	of	the	most	
important	things	that	we	have.	If	we	can't	
remember	what	we	did	last	week,	then	it	
must	reduce	our	quality	of	life	(Quote	3	005)
(5)	The	benefits	are	around	“soft	skills”	…	
feel	less	anxious,	feel	more	confident.	It	is	
the	relatives	who	report	this.	These	
benefits	help	families.	They	are	not	hard	
and	fast	benefits	such	as	“he	remembers	
such	and	such	better”	(Quote	5	HSP010)
(2)	What	I	don't	want	to	happen	is,	if	I	get	
violent,	I	don't	want	to	be	one	of	those	people	
that	now	start	beating	everybody	up,	or	you	
know,	anything	like	that.	Because	I	know	
people	do	get	violent,	(Quote	2	011)
(4)	I	think	possibly	that's	one	(memory)	that's	
always	in	the	centre	because	that	is	what	we	
associate	with	dementia.	I	don't	know	any	of	
the	lead‐up	signs	to	it	at	all	because	that's	
what everything about dementia and 
Alzheimer's	focuses	on.	So	if	there's	some	
smaller	lead‐up	indicators,	I	don't	know	what	
they	are	(Quote	4	003)
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Some	healthy	volunteers	did	not	initially	hesitate	to	consider	tak‐
ing	drugs	 to	prevent	dementia	when	asked	early	 in	 the	discussion	
about	 taking	 them.	However,	 they	 sounded	 a	more	 cautious	 note	
later	in	the	discussion	once	they	had	considered	the	various	trade‐
off	 between	 benefits	 and	 harmful	 side‐effects	 of	 drugs	 in	 more	
depth	(Table	10	Quote	2).
For	most	people	already	experiencing	memory	problems,	some	
of	whom	were	already	taking	currently	available	treatments	which	
aim	to	slow	progress,	the	decision	to	take	them	was	not	difficult	as	
they took them “because the doctor said so.” They were prepared to 
accept	the	uncertainty	of	both	benefits	and	chances	of	harmful	side‐
effects	(Table	10	Quote	3).
The	side‐effects	that	people	would	be	prepared	to	tolerate	var‐
ied	 across	 all	 participants	 and	 the	 discussion	 in	 both	 healthy	 vol‐
unteer	 groups	 and	 people	with	memory	 problem	 groups	 revolved	
around	the	severity	of	various	symptoms,	whether	or	not	symptoms	
could	be	alleviated	and	how	much	disruption	 they	would	cause	 to	
daily	life	(Table	10	Quote	4	and	Quote	5).	This	points	to	the	bottom	
line	of	weighing	up	harms	and	benefits	and	links	back	to	the	various	
aspects	 that	 matter	 in	 everyday	 life	 discussed	 earlier	 (Table	 10	 
Quote	6).
Healthy	volunteers	were	overall	more	able	 to	engage	 in	 think‐
ing	 about	 how	 to	 trade‐off	 the	 probability	 of	 benefitting	 from	 a	
drug	treatment	against	the	probability	of	experiencing	a	side‐effect	
(Table	10	Quote	7).
However,	 the	 complexity	 for	 everyone	 of	 making	 decisions,	
whereby	the	chance	of	benefitting	from	a	drug	treatment	has	to	be	
traded	off	against	the	chance	of	side‐effects	of	varying	degrees	of	
severity,	was	recognized	(Table	10	Quote	8).
Health	and	social	care	professionals	were	cautious	when	consid‐
ering	the	benefits	of	currently	available	drug	treatment	to	slow	or	
prevent	dementia	and	their	approach	was	to	manage	people's	expec‐
tation	and	be	honest	about	the	degree	of	benefit	they	could	expect	
(Table	10	Quote	9).
In	 terms	of	 the	 trade‐off	between	benefits	 and	harms	of	drug	
treatment,	 health	 professionals	 recognized	 that	 there	 has	 to	 be	 a	
“real‐life	benefit”	to	taking	medication,	otherwise	it	 is	not	worth	it	
(Table	10	Quote	10).
People with 
memory Healthy volunteers
Health and social 
care professionals
Not	
applicable
(1)	But	certainly,	30	per	cent	(chance	of	getting	
dementia),	I	would	probably	volunteer	for	any	sort	of	
new	trial	drug,	and	perhaps	even	less	than	30	per	cent.	
It's	just	because	the	only	thing	that	I	feel	defines	me	is	
my	mind,	my	thinking	process.	And	that	is	almost,	
when	that	starts	getting…starting	to	go,	or	to	fade	or	
to	get	worse…then	I	would	do	a	lot	to	prevent	that	
happening.	(Quote	1	010)
Not	applicable
(2)	My	biggest	fear	about	dementia,	and	I	am	absolutely	
convinced	I'll	get	it,	you	know,	having	seen	my	granny	
with	it,	my	mum	with	it,	every	time	I	forget	some‐
body's	face,	or	name,	or	anything,	I	think,	oh	is	this	it	
starting	now,	you	know,	and	I'm	beginning	to,	you	
know,	worry	about	that.	And	part	of	the	reason	I	
worry	about	is	the	impact	it	has	on	other	people	
around	you.	And	if	I	could	take	a	drug	that	meant	I	was	
less	of	a	burden	on	them,	for	longer,	I	would	abso‐
lutely	sign	up	for	that	(Quote	2	008)
(3)	As	far	as	the	care	goes,	I	know	in	nursing	homes,	
thinking	of	the	few	that	my	cousin	was	in,	they	get	to	a	
stage	where	the	patients	are	taken	into	a	chair,	
perhaps	in	a	room	with	other	folk,	perhaps	just	sitting	
up	in	their	own	little	room,	and	they're	left	and	that's	
it,	and	the	television	might	be	on,	and	they	might	talk	
to	somebody	else,	they	might	not,	and	we've	all	seen	
pictures	of	these	rooms	with	lots	of	armchairs	and	
people	sitting	in	them	and	that's	all	they	do.	So	the	
stimulation	and	keeping	the	brain	stimulated	doesn't	
happen,	which	is	very	distressing.	(Quote	3	003)
(4)	I'm	not	really	clear	on	what's	normal,	I	mean,	is	there	
a	sort	of,	are	there	detailed	definitions	of	what	sort	of	
normal	forgetfulness	is,	as	opposed	to	dementia	
forgetfulness?(Quote	4	010)
TA B L E  9  The	significance	of	reducing	
the	risk	of	developing	dementia	with	
drugs	(Each	quote	labelled	with	quote	
number	plus	unique	identifier	code	of	
each	participant)
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4  | DISCUSSION
The	paradigm	 shift	 towards	prevention	of	AD	where	 clinical	 trials	
now	 seek	 to	 enrol	 people	with	mild	 cognitive	 impairment	 and	 no	
cognitive	impairment	has	raised	new	methodological	and	analytical	
challenges	 which	 require	 understanding.	 This	 paper	 presents	 re‐
search	that	addresses	two	of	these	challenges:	understanding	what	
outcomes	matters	 to	 people	 taking	 part	 in	 trials	 for	 preventative	
drugs,	 and	 understanding	 how	 people	 think	 about	 making	 trade‐
offs	 between	 potential	 harms	 and	 benefits	 of	 preventative	 drugs.	
It	forms	the	second	stage	of	the	ePSOM	development	programme	
which	ultimately	aims	to	develop	an	app	for	measuring	person‐spe‐
cific	outcomes	in	clinical	drug	trials	for	the	prevention	of	Alzheimer's	
disease.	 This	 study	 explored	 these	 issues	 from	 the	perspective	of	
people	with	subjective	cognitive	impairment,	mild	cognitive	impair‐
ment,	mild	Alzheimer's	disease,	healthy	volunteers	and	health	and	
social	 care	 professionals	 providing	 care	 to	 people	 with	 dementia.	
This	is	a	key	strength	of	the	study.	A	limitation	is	the	absence	of	fam‐
ily	or	informal	carers.	It	is	known	that	the	experiences	and	views	of	
family	and	informal	carers	can	differ	from	those	of	people	living	with	
dementia.25	The	healthy	volunteer	group	did	however	include	some	
people	 with	 experience	 of	 informal	 caring	 which	 counteracts	 the	
limitations	to	some	degree.	The	blurring	of	the	lines	and	overlap	be‐
tween	people	in	the	healthy	volunteer	groups	and	the	memory	prob‐
lems	groups	 reflects	 the	blurring	of	 the	 lines	between	 the	degree	
of	memory	 loss	attributed	 to	normal	ageing	and	the	continuum	of	
Alzheimer's	disease.26	Jack	et	al26	suggest	that	a	biologically	based	
definition	of	the	disease	using	biomarkers	including	the	pre‐clinical	
phase	is	needed	for	intervention	studies.	Biomarker	characterization	
of	our	sample	was	well	beyond	the	scope	of	our	study	and	reflects	
the	challenges	of	research	in	the	field	and	the	difficulty	of	defining	
a	sample.
TA B L E  1 0  Balancing	Risks	against	Benefits	from	the	perspective	of	people	with	memory	problems,	healthy	volunteers	and	health	and	
social	care	professionals	(Each	quote	labelled	with	quote	number	plus	unique	identifier	code	of	each	participant)
People with memory problems Healthy volunteers Health and social care professionals
(3)	I	didn't	give	it	that	depth	of	thought	that	
I	should	have,	but	if	I	knew	there	were	
side	effects,	I	would	still	take	it	to	see	if	
they	affected	me	in	any	way,	or	what,	
which	of	them	did	affect	me,	and	then	it	
would	depend	on	how	serious	that	was.	
(Quote	3	028)
(1)	I	don't	think	I'd	want	to	know	(my	chances	of	
getting	dementia)	because	I	think	it	would	affect	how	
I	encompass	my	life.	I	think	I	would	have	this	worry	
hanging	over	me.	I'd	rather	carry	on	in	blissful	
ignorance….there's	not	a	fix	for	this,	so	I	think	I'd	
rather	not	know.	If	I	had	something	that	was	fixable,	
I'd	want	to	know	and	get	it	fixed,	but	this	is	your	
unknown…(Quote	1	004)
(9)	It	might	mean	they	ask	3	times	a	day	
what	day	it	is	instead	of	6	times	a	day,	
or	it	might	mean	the	person	starts	
watching	TV	again,	starts	enjoying	
watching	rugby	again—subtle	benefits.	
People	are	prepared	to	take	treatment	
for	these	subtle	benefits.	(Quote	9	
HSP008)
(5)	Well,	any	of	the	side	effects,	if	it	went	
on	for	too	long,	would	then	make	you	
mentally	low,	so	there	is	no	point,	because	
the	disease	itself	would	be	deteriorating,	
just	because	you	were	depressed	and	low	
and	mentally	not	able	to	cope	(Quote	5	
022)
(2)	I	think	I	would	probably	have	to	withdraw	my	
original	statement	about	not	hesitating	(to	take	
preventative	drugs).	I	wouldn't	hesitate	to	think	
about	it,	but	obviously	these	risks	and	benefits	would	
have	to	come	into	the	decision	process.	So	I	probably	
would	hesitate	a	little	bit…	I	certainly	would	be	quite	
keen	to	consider	taking	part	in	any	trials,	but	if	
information	came	out	about	some	of	the	side	effects,	
I	might	have	second	thoughts.	(Quote	2	005)
(10)	People	said	things	like	“my	husband	
is	better	but	we	can't	go	out	any	more	
because	he	needs	the	toilet	every	5	
minutes,”	“they	have	diarrhoea	so	we	
can't	go	anywhere”—there	has	to	be	a	
real	life	benefit—there	was	a	trade‐off	
between	having	an	upset	tummy	and	
not	feeling	safe	going	anywhere	
against	not	feeling	safe	going	
anywhere	because	the	person	is	
muddled.	People	stopped	drugs	for	
this	reason.	(Quote	10	HSP007)
(6)	If	the	side‐effects	made	your	lifestyle	
worse,	then	there's	no	point	in	taking	it.	
(Quote	6	014)
(4)	A	lot	of	it	would	depend	on	whether	you	could	
treat	the	side‐effects.	So	if	headaches	was	a	
side‐effect,	a	known	side‐effect	of	a	drug	that	I	was	
gonna	be	put	on,	or	I	was	choosing	to	go	onto,	I'd	say,	
well,	and	is	there	any	way	of	treating	the	symptoms.	
So,	you	know,	if	I've	got	something,	that	should	the	
headache	come	on,	I	take	something,	and	that	solves	
that,	I'd	be	reasonably	okay.	And	I	think,	you	know,	
tiredness,	fine,	you	can	go	to	bed,	dizziness	that	
might	be	more	difficult	to	live	with,	unless	you	can	
find	a	cure	for	it.	Stomach	problems,	how	disruptive	
to	your	daily	life	will	it	be?	(Quote	4	008)
 
(8)	Side	effects	are	always	defined	in	terms	
of	probability,	and	I	think	most	people	
have	difficulty	in	looking	at	probability	as	
a	subject	because	it's	not	at	all	simple. 
(Quote	8	029)
(7)	If	there's	an	80	per	cent	chance	of	the	drug	being	
effective,	and	a	20	per	cent	chance	of	getting	
dizziness,	actually,	you	know,	that	sounds	like	
reasonably	worth	throwing	the	dice	for.	(Quote	7	
008)
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The	findings	highlight	that	what	matters	 in	developing	new	treat‐
ments	to	prevent	Alzheimer's	disease	mirrors	what	matters	in	everyday	
life	 and	needs	 to	attend	 to:	Everyday	Functioning,	 Sense	of	 Identity,	
Relationships	 and	 Social	 Connections,	 Enjoying	 Life	 and	 Alleviating	
Symptoms.	Many	aspects	of	Everyday	Functioning,	such	as	being	able	
to	get	washed	and	dressed,	were	common	across	and	within	groups.	
This	was	linked	to	worries	about	becoming	a	burden	on	family.	These	
domains	are	informing	the	development	of	the	survey,	the	next	stage	
of	 the	 ePSOM	 development	 programme.	 Some	 problems,	 such	 as	
putting	your	clothes	on	 in	 the	 right	order,	are	 technically	not	 related	
to	memory	but	executive	functioning	 involving	different	parts	of	 the	
brain.	However,	they	were	spoken	about	and	identified	by	lay	people	
as	“memory”	problems.	This	distinction	is	important	to	clarify	in	the	de‐
velopment	of	the	survey	and	for	future	participants	in	clinical	trials	as	
it	 is	 relevant	 to	 the	understanding	of	measuring	 the	effectiveness	of	
interventions.
The	inclusion	of	people	currently	 living	with	memory	problems	
gave	insights	into	the	subtle	ways	that	confidence	is	lost	due	to	for‐
getting	words	and	names	and	Relationships	and	Social	Connections	
are	eroded.	These	subtle	changes	and	 the	presence	or	absence	of	
them	will	be	useful	 indicators	of	the	effectiveness	or	otherwise	of	
preventative	drugs	in	future	trials.
It	 was	 recognized	 that	 how	 people	 define	 “Enjoying	 Life”	 is	
individual,	 and	 therefore,	 measuring	 the	 effectiveness	 of	 new	
treatments	on	 their	ability	 to	help	people	continue	to	enjoy	 life	
needs	 to	be	personalized	 to	 some	extent.	This	personalized	ap‐
proach	is	integral	to	the	development	of	the	ePSOM	app.	It	must	
also	be	noted	 that	measures	of	effectiveness	 in	clinical	 trials	 to	
slow	 or	 prevent	 dementia	 take	 place	 in	 the	 context	 of	 broader	
health	issues	and	the	physical	effects	of	ageing	which	can	impact	
on	the	ability	to	enjoy	life.	This	further	adds	to	the	complexity	of	
measuring	 effectiveness	 in	 clinical	 trials	 to	 prevent	Alzheimer's	
disease.
Our	results	show	that	previous	experiences	of	having	known	
or	cared	for	someone	with	dementia	shaped	views	of	the	signifi‐
cance	of	living	with	the	possibility	of	developing	dementia	in	the	
future.	This	is	in	keeping	with	previous	studies.27	Connected	with	
this	 was	 the	 view	 that	 we	 are	 defined	 by	 our	minds:	 dementia	
was	 seen	 as	 taking	 away	 the	mind	 and,	 by	 implication,	 the	per‐
son.	Being	defined	by	 “my	mind”	 reflects	 contemporary	 culture	
which	holds	rationality,	cognition	and	memory	as	core	aspects	of	
the	self.28	When	dementia	 leads	 to	 the	 loss	of	 these	aspects	of	
selfhood,	the	person	is	diminished	in	the	eyes	of	society	and,	as	
shown	here,	in	their	own	eyes.	Insights	from	some	of	the	people	
with	memory	 problems	 show	 how	 they	 felt	 like	 “I'm	 not	 there”	
when	family	members	denied	them	the	opportunity	to	continue	
with	 everyday	 tasks	 such	 as	 doing	 the	 ironing.	 Milne	 et	 al	 (p.	
982)27	describe	this	as	being	“corporeally	present	but	cognitively	
absent”	and	 it	underlines	how	overlooking	embodied	aspects	of	
selfhood29	 leads	 to	 exclusion	 and	 suffering	 of	 people	 with	 de‐
mentia	 as	 they	 become	 seen	 as	 non‐persons.	 This	 may	 shape	
views	 of	 risk	 decisions	 about	 developing	 dementia	 in	 powerful	
ways.	Hearing	the	direct	experience	of	those	already	experienc‐
ing	this	is	important	as	it	highlights	that	some	of	the	solutions	to	
the	 loss	of	 identity	 can	be	 found	 in	 changing	 attitudes	 towards	
people	with	dementia	and	creating	enabling	rather	than	disabling	
environments.
As	with	previous	studies,	people	were	able	to	engage	to	a	degree	
with	thinking	about	trade‐offs	between	harms	and	benefits	in	clin‐
ical	trials.14	However,	engaging	with	the	probability	of	harm	against	
the probability	of	benefit	was	more	challenging	for	those	with	mem‐
ory	problems.	The	challenges	of	making	probabilistic	judgements	are	
an	 important	consideration	going	 forward	 in	 the	ePSOM	develop‐
ment programme.
Our	results	suggest	that	the	assessment	of	risk	and	how	much	
potential	harm,	in	the	form	of	side‐effects,	a	person	is	prepared	to	
accept	may	 also	 be	 shaped	by	 fears	 about	 inadequate	 care	 provi‐
sion	 in	care	homes.	Efforts	to	provide	new	models	of	care	to	sup‐
port	social	 inclusion	of	people	with	dementia30	and	fix	the	broken	
image	of	care	homes31	may	alleviate	some	of	this	fear	in	the	future	
and	 change	 people's	 assessment	 of	 the	 harmful	 consequences	 of	
developing	 dementia.	 Drug	 development	 is	 a	 long	 process.	 Until	
such	times	as	effective	preventative	drug	treatments	are	developed,	
there	is	still	much	that	can	be	achieved	using	these	non‐pharmaco‐
logical	approaches	to	address	some	of	the	aspects	of	everyday	life	
that	matter	to	people	living	with	dementia	and	those	who	may	de‐
velop	it	in	the	future.
5  | CONCLUSIONS
This	 study	 gives	 insights	 into	 the	 aspects	 of	 everyday	 life	
which	are	important	to	consider	when	measuring	the	effective‐
ness	 of	 new	 treatment	 to	 slow	 and	 prevent	 dementia,	 namely	
Everyday	 Functioning,	 Sense	 of	 Identity,	 Relationships	 and	
Social	 Connections,	 Enjoying	 Life	 and	 Alleviating	 Symptoms.	
Also,	it	provides	insights	into	how	people	assess	the	significance	
of	reducing	the	risk	of	dementia	with	drugs,	and	how	they	weigh	
up	 benefits	 and	 potential	 harms	 of	 drugs.	 The	 perspectives	 of	
people	experiencing	memory	problems,	healthy	volunteers	and	
health	 and	 social	 care	 professionals	 are	 compared	 and	 con‐
trasted.	In	the	ePSOM	programme,	the	focus	groups	were	a	vital	
bridge between the literature review13	and	the	population	sur‐
vey	to	be	implemented	in	the	UK	in	early	2019.	They	defined	the	
five	key	themes	to	be	used	in	the	survey	as	well	as	highlighting	
key	distinctions	of	emphasis	between	health‐care	professionals,	
people	experiencing	memory	problems	and	those	at	 (apparent)	
high	risk	of	dementia.	The	fourth	stage	of	the	project,	that	is	the	
development	 and	delivery	of	 the	outcome	 assessment	 tool	 for	
use	in	clinical	trials,	will	hence	be	directly	informed	by	all	three	
preceding	steps:	literature	review,	focus	groups	and	population	
survey.
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